In patients for whom biological therapy has failed, the use of drugs like mavrilimumab (an antibody against GM-CSF), rituximab (an Anti CD20 antibody), and tocilizumab (rheumatoid arthritis is a multifactorial disease that blocks IL6) were encouraging [103,104]. The gene discussed is MS4A1; the disease is rheumatoid arthritis.